1283108-77-9

Upstream product

• 150879-48-4 N-methyl-N-methyloxy-2-amino-5-chlorobenzamide 
• 4743-17-3 5-Chloroisatoic anhydride 
• 837-58-1 2-amino-4'-chloro-5-chlorobenzophenone 
• 141-97-9 ethyl acetoacetate 
• 106-39-8 bromochlorobenzene 
• 635-21-2 5-chloroanthranilic acid 

Downstream Products

• 1449373-31-2 (E)-6-chloro-4-(4-chlorophenyl)-3-[3-(4-chlorophenyl)acryloyl]quinolin-2(1H)-one 
• 1449374-20-2 4-{3-[6-chloro-4-(4-chlorophenyl)-2-oxo-1,2-dihydroquinolin-3-yl]-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl}-4-oxobutanoic acid 

Relevant academic research and scientific papers

Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma

The protein Kinase B alpha (AKT) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways are central regulators of cellular signaling events at the basis of tumor development and progression. Both pathways are often up-regulated in different tumor types including melanoma. We recently reported the identification of compound 1 (BI-69A11) as inhibitor of the AKT and the NF-κB pathways. Here, we describe SAR studies that led to novel fluorinated derivatives with increased cellular potency, reflected in efficient inhibition of AKT and IKKs. Selected compounds demonstrated effective toxicity on melanoma, breast, and prostate cell lines. Finally, a representative derivative showed promising efficacy in an in vivo melanoma xenograft model. We describe SAR studies that led to compound 42 as a potent cellular inhibitor of phosphorylation of AKT1-3 and the NF-κB pathway in melanoma, breast, and prostate cell lines and showed remarkable efficacy in an in vivo melanoma xenograft model with the drug administered orally.

Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists

Here we describe the synthesis and structure-activity relationship for a class of pyrazoline-containing dihydroquinolone negative allosteric modulators of the NMDA receptor that show strong subunit selectivity for GluN2C- and GluN2D-containing receptors over GluN2A- and GluN2B-containing receptors. Several members of this class inhibit NMDA receptor responses in the nanomolar range and are more than 50-fold selective over GluN1/GluN2A and GluN1/GluN2B NMDA receptors, as well as AMPA, kainate, GABA, glycine, nicotinic, serotonin, and purinergic receptors. Analysis of the purified enantiomers of one of the more potent and selective compounds shows that the S-enantiomer is both more potent and more selective than the R-enantiomer. The S-enantiomer had an IC 50 of 0.17-0.22 μM at GluN2D- and GluN2C-containing receptors, respectively, and showed over 70-fold selectivity over other NMDA receptor subunits. The subunit selectivity of this class of compounds should be useful in defining the role of GluN2C- and GluN2D-containing receptors in specific brain circuits in both physiological and pathophysiological conditions.